Because neither the NCI-H441 nor the U87MG tumor models is MET amplified, these results suggest that ABT-700 in combination with existing therapies may broaden177 the clinical indications beyond those tumors with MET amplification to those tumors with c-Met overexpression, or autocrine HGF stimulation. Here, HGF is linked to neoplasm.